Connection

GUILLERMINA LOZANO to Gene Expression Regulation, Neoplastic

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Gene Expression Regulation, Neoplastic.
  1. p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes Dev. 2020 09 01; 34(17-18):1128-1146.
    View in: PubMed
    Score: 0.235
  2. Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration. Proc Natl Acad Sci U S A. 2018 02 27; 115(9):2198-2203.
    View in: PubMed
    Score: 0.197
  3. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes Dev. 2017 09 15; 31(18):1847-1857.
    View in: PubMed
    Score: 0.192
  4. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011 Dec 01; 71(23):7168-75.
    View in: PubMed
    Score: 0.127
  5. New mouse models of cancer: single-cell knockouts. Proc Natl Acad Sci U S A. 2007 Mar 13; 104(11):4245-6.
    View in: PubMed
    Score: 0.092
  6. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol. 2006 Jun; 16(3):225-34.
    View in: PubMed
    Score: 0.087
  7. p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell. 2005 Feb; 7(2):113-4.
    View in: PubMed
    Score: 0.080
  8. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Res Commun. 2024 08 01; 4(8):1991-2007.
    View in: PubMed
    Score: 0.077
  9. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 2017 Apr 18; 8(16):25837-25847.
    View in: PubMed
    Score: 0.047
  10. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol. 2017 03; 241(4):501-510.
    View in: PubMed
    Score: 0.046
  11. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene. 2016 Jan 21; 35(3):358-65.
    View in: PubMed
    Score: 0.041
  12. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol. 2015 Feb; 62(2):371-9.
    View in: PubMed
    Score: 0.039
  13. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19.
    View in: PubMed
    Score: 0.038
  14. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11.
    View in: PubMed
    Score: 0.038
  15. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904.
    View in: PubMed
    Score: 0.030
  16. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest. 2011 Mar; 121(3):851-65.
    View in: PubMed
    Score: 0.030
  17. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog. 1991; 4(1):3-9.
    View in: PubMed
    Score: 0.030
  18. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008 May 15; 22(10):1337-44.
    View in: PubMed
    Score: 0.025
  19. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19842-7.
    View in: PubMed
    Score: 0.023
  20. What have animal models taught us about the p53 pathway? J Pathol. 2005 Jan; 205(2):206-20.
    View in: PubMed
    Score: 0.020
  21. Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunol Res. 2024 Sep 03; 12(9):1170-1183.
    View in: PubMed
    Score: 0.019
  22. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14849-54.
    View in: PubMed
    Score: 0.017
  23. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun. 2021 09 10; 12(1):5389.
    View in: PubMed
    Score: 0.016
  24. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nat Commun. 2019 11 26; 10(1):5385.
    View in: PubMed
    Score: 0.014
  25. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology. 2018 07; 155(1):210-223.e3.
    View in: PubMed
    Score: 0.012
  26. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 1998 Feb 15; 58(4):698-703.
    View in: PubMed
    Score: 0.012
  27. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Mol Cell. 2016 Jan 07; 61(1):68-83.
    View in: PubMed
    Score: 0.011
  28. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
    View in: PubMed
    Score: 0.011
  29. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-?-driven epithelial-mesenchymal transition. Cancer Discov. 2013 Oct; 3(10):1172-89.
    View in: PubMed
    Score: 0.009
  30. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012 Jun 12; 21(6):793-806.
    View in: PubMed
    Score: 0.008
  31. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011 Jul 12; 20(1):79-91.
    View in: PubMed
    Score: 0.008
  32. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest. 2007 Jul; 117(7):1893-901.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.